High-affinity immunoglobulin epsilon receptor (FcεRI) complexed with Dermatophagoides-specific IgE (FcεRI-IgE (HDM))

The Dermatophagoides-specific IgE-FcεRI complex is a critical molecular assembly on the surface of mast cells and basophils that mediates allergic responses to house dust mites (HDM). This complex consists of the high-affinity IgE receptor (FcεRI) and HDM-specific Immunoglobulin E (IgE) antibodies, which are produced by B cells in response to allergens from species like Dermatophagoides pteronyssinus or Dermatophagoides farinae (PubMed: 26044852). When HDM allergens encounter these sensitized cells, they cross-link the receptor-bound IgE molecules, initiating an intracellular signaling cascade that triggers the rapid release of inflammatory mediators such as histamine and leukotrienes (PubMed: 11781634). This degranulation process is the primary driver of clinical symptoms in allergic asthma, allergic rhinitis, and atopic dermatitis (PubMed: 21269297). Therapeutic interventions, such as the monoclonal antibody Omalizumab, target this pathway by binding to free IgE, thereby preventing its association with FcεRI and leading to a subsequent downregulation of the receptor on the cell surface (PubMed: 12487211). Additionally, allergen-specific immunotherapy (AIT) aims to modify the immune response to this complex by inducing desensitization and regulatory T-cell activity (PubMed: 28212942). Monitoring of this target is typically performed through the measurement of allergen-specific IgE levels or functional assays like the basophil activation test.

Other names

House dust mite-specific IgE-FcεRI complexHDM-IgE-FcεRI signaling complexDermatophagoides-specific IgE-FcεRI complex

Omalizumab and ligelizumab bind to the Cε3 domain of free IgE, preventing its interaction with the FcεRI receptor on mast cells and basophils, which subsequently leads to the downregulation of FcεRI expression (PubMed: 12487211). Allergen-specific immunotherapy (AIT) involves the administration of Dermatophagoides extracts to induce immunological tolerance, shifting the immune response from a Th2-mediated allergic profile to a Th1/Treg-mediated regulatory profile, thereby reducing the activation of the IgE-FcεRI complex (PubMed: 28212942).